SI-BONE, Inc. reported a revenue of $52.6 million for the first quarter of 2026, marking an 11.2% increase from $47.3 million in the same period of the previous year. The company's gross profit also rose to $41.9 million, up from $37.7 million, resulting in a stable gross margin of 79.8%. Despite the increase in revenue, SI-BONE recorded a net loss of $4.3 million, an improvement from the $6.5 million loss reported in the first quarter of 2025. The company attributed the revenue growth primarily to higher procedure volumes in the U.S., driven by expanded product adoption and increased sales channel coverage.
In terms of operational metrics, SI-BONE's U.S. commercial organization expanded its workforce, including 89 territory sales managers and 336 third-party sales agents as of March 31, 2026, compared to 85 and 278, respectively, a year earlier. The company has performed nearly 150,000 procedures using its technologies since commercialization. International revenue also saw a significant increase, rising 33.9% to $3.3 million, although it still represented a small portion of total revenue.
The company’s operating expenses increased to $47.0 million from $45.2 million year-over-year, primarily due to higher sales and marketing costs, which rose by 6.9% to $32.8 million. Research and development expenses decreased slightly to $4.2 million, reflecting the timing and stage of various product development projects. General and administrative expenses remained relatively stable, increasing marginally to $10.0 million.
SI-BONE's cash and marketable securities totaled $144.7 million as of March 31, 2026, down from $147.8 million at the end of 2025. The company continues to maintain a significant accumulated deficit of $454.6 million. Looking ahead, SI-BONE expects to continue investing in research and development to support new product launches and enhance its market position. The company remains cautious about potential economic downturns and market conditions that could impact its financial performance and may require additional capital in the future.
About SI-BONE, Inc.
SI-BONE, Inc. develops minimally invasive surgical implant systems for musculoskeletal disorders of the sacropelvic anatomy, focusing on sacroiliac joint dysfunction, pelvic fixation, and fractures. Its core products include patented titanium implants and related instruments, supported by extensive clinical evidence. Serving global markets, the company emphasizes innovative solutions, physician training, and strong regulatory compliance to improve patient outcomes in spine and pelvic surgeries.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.